Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215,278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ. Kater AP, et al. Among authors: wang j. J Clin Oncol. 2019 Feb 1;37(4):269-277. doi: 10.1200/JCO.18.01580. Epub 2018 Dec 3. J Clin Oncol. 2019. PMID: 30523712 Free article. Clinical Trial.
Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.
Deng R, Gibiansky L, Lu T, Agarwal P, Ding H, Li X, Kshirsagar S, Lu D, Li C, Girish S, Wang J, Boyer M, Humphrey K, Freise KJ, Salem AH, Seymour JF, Kater AP, Miles D. Deng R, et al. Among authors: wang j. Clin Pharmacokinet. 2019 Dec;58(12):1621-1634. doi: 10.1007/s40262-019-00788-8. Clin Pharmacokinet. 2019. PMID: 31209657 Clinical Trial.
Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
Deng R, Gibiansky L, Lu T, Li X, Lu D, Li C, Girish S, Wang J, Boyer M, Shankar N, Humphrey K, Freise KJ, Salem AH, Seymour JF, Kater AP, Miles D. Deng R, et al. Among authors: wang j. Leuk Lymphoma. 2020 Jan;61(1):56-65. doi: 10.1080/10428194.2019.1657575. Epub 2019 Sep 24. Leuk Lymphoma. 2020. PMID: 31549889 Clinical Trial.
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
Kater AP, Wu JQ, Kipps T, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Dubois J, Eldering E, Mellink C, Van Der Kevie-Kersemaekers AM, Kim SY, Chyla B, Punnoose E, Bolen CR, Assaf ZJ, Jiang Y, Wang J, Lefebure M, Boyer M, Humphrey K, Seymour JF. Kater AP, et al. Among authors: wang j. J Clin Oncol. 2020 Dec 1;38(34):4042-4054. doi: 10.1200/JCO.20.00948. Epub 2020 Sep 28. J Clin Oncol. 2020. PMID: 32986498 Free PMC article. Clinical Trial.
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.
Konopleva MY, Dail M, Daver NG, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Dunshee DR, Hamidi H, Ott MG, Hong WJ, Andreeff M. Konopleva MY, et al. Among authors: wang j. Clin Lymphoma Myeloma Leuk. 2024 Jun;24(6):364-374. doi: 10.1016/j.clml.2024.01.007. Epub 2024 Jan 18. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38378362 Free article. Clinical Trial.
Comparative effectiveness between mosunetuzumab monotherapy clinical trial and real-world data in relapsed/refractory follicular lymphoma in third or subsequent lines of systemic therapy.
McGough SF, Shamas N, Wang J, Jaber M, Swarup B, Blanchet Zumofen MH, Lautié B, Parreira J, Wei MC, Shewade A. McGough SF, et al. Among authors: wang j. Leuk Lymphoma. 2023 Dec;64(14):2269-2278. doi: 10.1080/10428194.2023.2262066. Epub 2023 Dec 25. Leuk Lymphoma. 2023. PMID: 37840271
215,278 results
You have reached the last available page of results. Please see the User Guide for more information.